Q-omics provides the consensus-scored LINC01526 profile across patient tissues and cancer cell-line models. LINC01526 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LINC01526 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LINC01526 RNA expression shows 6,987 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where LINC01526 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01526 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01526 survival associations across molecular data types. LINC01526 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01526 RNA expression–survival associations across cancer types. High LINC01526 expression shows unfavorable associations in CESC, STAD, GBM and ACC, but favorable associations in UCS and KIRP. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for LINC01526 RNA expression.
This table summarizes LINC01526 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01526. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01526 shows lower tumor expression in LUAD and higher tumor expression in KIRC, HNSC, KICH, THCA and KIRP. The KIRC box plot shows higher LINC01526 RNA expression in tumor versus normal tissue (log2 FC = +0.255, t-test p < 0.001).
This table shows molecular features associated with LINC01526 in patient tissues and cancer cell lines. In patient samples, LINC01526 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
